BioMarin Raises 2025 Revenue Guidance as PALYNZIQ and VOXZOGO Sales Climb 20%
BioMarin Pharmaceutical Inc. reported operating cash flows totaling $369 million for the third quarter of 2025, and $728 million in year-to-date operating cash flows. Total cash, cash equivalents, and investments were $2.0 billion as of September 30, 2025, compared to $1.66 billion at December 31, 2024. The company updated its 2025 full-year financial guidance to reflect acquired in-process research and development charges of $221 million on a pre-tax basis related to the acquisition of Inozyme. The company also revised its Non-GAAP Operating Margin and Non-GAAP Diluted EPS guidance to include the impact of these charges. Weighted-average diluted shares outstanding for Non-GAAP Diluted EPS guidance is approximately 200 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF07455) on October 27, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。